Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Polyphor AG    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/07/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
11.36(c) 11.44(c) 11.1(c) 11.42(c) 11.08(c) Last
13 651 17 258 31 405 20 257 20 034 Volume
-5.18% +0.70% -2.97% +2.88% -2.98% Change
More quotes
Financials (CHF)
Sales 2019 23,2 M
EBIT 2019 -51,2 M
Net income 2019 -68,8 M
Finance 2019 80,6 M
Yield 2019 -
Sales 2020 7,59 M
EBIT 2020 -45,1 M
Net income 2020 -51,6 M
Finance 2020 36,0 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 1,94x
EV / Sales2020 11,8x
Capitalization 126 M
More Financials
Company
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas... 
Sector
Pharmaceuticals
Calendar
09/05Earnings Release
More about the company
Surperformance© ratings of Polyphor AG
Trading Rating : Investor Rating :
More Ratings
Latest news on POLYPHOR AG
06/07POLYPHOR : presents new in-vivo efficacy and tolerability data for a potential i..
EQ
05/29POLYPHOR : and the University of Zurich receive an award from Innosuisse to acce..
EQ
05/17POLYPHOR : announces presentation of new survival data on balixafortide at the A..
EQ
05/09POLYPHOR : temporarily halts enrollment in the Phase III studies of murepavadin ..
EQ
04/17POLYPHOR : announces enrollment of first patient in PRISM-UDR - the second, FDA ..
AQ
04/17POLYPHOR : presents new data at ECCMID from its lead antibiotic murepavadin and ..
EQ
04/16POLYPHOR : announces enrollment of first patient in PRISM-UDR - the second, FDA ..
EQ
04/12POLYPHOR : shareholders approve all motions proposed by the Board of Directors a..
EQ
04/12POLYPHOR : antibiotic murepavadin receives US FDA Qualified Infectious Disease P..
EQ
04/09POLYPHOR : appoints Gökhan Batur as Chief Commercial Officer
EQ
More news
Sector news : Biopharmaceuticals
06/15Drug Firms Sue Over Ad Rule -- WSJ
DJ
06/14Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy--Update
DJ
06/14BAYER : Deutsche Bahn to Phase out Glyphosate -WirtschaftWoche
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy
DJ
More sector news : Biopharmaceuticals
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 20,0  CHF
Spread / Average Target 76%
EPS Revisions
Managers
NameTitle
Giacomo di Nepi Chief Executive Officer
Argeris N. Karabelas Chairman
Kalina Scott Chief Financial Officer
Daniel Obrecht Chief Scientific Officer
Frank Weber Director, Chief Medical & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
POLYPHOR AG-37.89%131
CSL LIMITED14.97%64 329
BIOGEN-24.34%43 310
ALEXION PHARMACEUTICALS20.42%25 574
SAMSUNG BIOLOGICS CO LTD--.--%16 821
GRIFOLS5.72%16 048